Comparative Pharmacology
Head-to-head clinical analysis: OXCARBAZEPINE versus TOPAMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXCARBAZEPINE versus TOPAMAX.
OXCARBAZEPINE vs TOPAMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilization of neuronal membranes by blockade of voltage-sensitive sodium channels, leading to inhibition of repetitive firing and reduction of neurotransmitter release.
Antiepileptic; modulates voltage-gated sodium channels, enhances GABA-A activity, antagonizes AMPA/kainate glutamate receptors, weakly inhibits carbonic anhydrase.
Initial 300 mg orally twice daily; increase by 300 mg/day every third day to target dose of 600-1200 mg/day in two divided doses. Maximum 2400 mg/day.
Initial dose 25 mg orally twice daily; titrate by 25-50 mg weekly to effective dose; usual maintenance dose 200-400 mg/day divided twice daily; maximum 1600 mg/day.
None Documented
None Documented
Clinical Note
moderateOxcarbazepine + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Cobicistat
"The serum concentration of Cobicistat can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Saxagliptin
Oxcarbazepine: 2 hours (parent drug); MHD (active metabolite): 9 hours. Steady-state achieved in 2-3 days. Context: shorter t1/2 than carbamazepine; MHD t1/2 extended in renal impairment (up to 19 hours).
Terminal elimination half-life is 21 hours (range 18-23 hours). Linear pharmacokinetics. Half-life is prolonged in renal impairment (CrCl <70 mL/min: ~35 hours).
Renal: 70% (mainly as glucuronide metabolites, unchanged drug <1%). Fecal: negligible.
Renal: ~70% (unchanged drug); remainder as metabolites. Biliary/fecal: minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Saxagliptin can be decreased when it is combined with Oxcarbazepine."